Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Summary of trials addressing systemic therapy in advanced breast cancer

From: Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer

Author, year Institution(s)/ Database Population Time intervals Comments
Andre, 2004 [5] France (3 institutions) 724 women de novo metastatic breast cancer 1987-1993 Excluded supraclavicular lymph node only patients. Improved 3 year overall survival (OS; 44% vs 27%) was seen in the more recent time period.
    1994-2000  
Giordano, 2004 [9] MD Anderson Cancer Center 834 women with recurrence after adjuvant doxorubicin 1974-1979 Included patients with locally recurrent disease. Predictors of improved overall survival included stage at diagnosis, interval disease-free survival, and dominant metastatic site.
    1980-1984  
    1985-1989  
    1990-1994  
    1995-2000  
Chia, 2007 [6] British Columbia Cancer Agency 2150 women with both recurrent and de novo metastatic breast cancer 1991-1992 An improvement in overall survival was noted over time, primarily in those patients that were hormone-receptor positive.
    1994-1995  
    1997-1998  
    1999-2001  
Dawood, 2008 [13] Surveillance, Epidemiology, and End Results Registry 15,438 women with both recurrent and de novo metastatic breast cancer 1988-1993 There was a modest improvement in overall survival, associated with patients with hormone-receptor positive disease. Outcomes appeared to be worse in African American women.
    1994-1998  
    1999-2002  
    2003-2006  
Dafni, 2009 [14] Hellenic Cooperative Group 1361 enrolled on trials for treatment of recurrent and de novo metastatic breast cancer 1991-1994 Trastuzumab used in 24% and 30% of patients in the two most recent time intervals.
    1995-1998  
    1999-2003  
Ruiterkamp, 2011 [10] Netherlands 8031 women with both recurrent and de novo metastatic breast cancer 1995-1999 10% of patients in third time interval received targeted therapy.
    2000-2004  
    2005-2008  
Pal, 2011 City of Hope 274 de novo metastatic breast cancer only 1985-1994 Overall survival improved for those receiving endocrine therapy, but no apparent overall survival benefit with newer chemotherapeutic agents.
    1995-2004